お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は市中肺炎（CAP）市場規模の世界市場の概要を紹介します。2019~2023年の歴史的な市場収益データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。レポートは市中肺炎（CAP）の主要メーカーを詳細に分析し、地域別・国別の収益プロフィールを明らかにしています。 本レポートでは特に、主要地域/国別のセグメントとサブセグメントについて、将来の市場ポテンシャルの探索と予測に焦点を当てています。 複数の地域にわたる包括的なデータと市場価値分析により、読者は包括的かつ詳細な市場洞察を得ることができます。

世界の市中肺炎（CAP）市場の主な参加者である企業概要、収益、粗利益率、ポートフォリオ、地理的位置、重要な発展について、次のパラメータに基づいて説明します。レポートは市中肺炎（CAP）のメーカー、地域、種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、タイプとアプリケーション/端末業界別に市中肺炎（CAP）市場を分類しています。本研究に含まれる主な企業は：Pfizer、Astrazeneca、Bioaegis Therapeutics、Biotest、C10 Pharma、Kyorin Pharmaceutical、Melinta Therapeutics、Merck、Nabriva Therapeutics、Paratek Pharmaceuticals

地域別市場区分、地域別分析は以下の通り：
    アメリカとカナダ
    中国
    アジア
    ヨーロッパ
    中東、アフリカ、ラテンアメリカ

タイプ別市場セグメント：
    Chest X-ray/Radiography
    Sputum Gram Stain and/or Culture
    Blood Cultures

用途別の市場セグメント：
    Hospitals and Clinics
    Others

本レポートの詳細内容
世界の市中肺炎（CAP）市場の現状と将来について、グローバルの主要地域を中心に包括的に分析しています。 当レポートでは、多角的な分析を通じて、市場プレイヤー、地域分布、市中肺炎（CAP）タイプ、最終用途アプリケーションなどの主要分野を掘り下げ、読者に包括的な市場洞察を提供しています。 レポートは主要企業の市中肺炎（CAP）収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界の市中肺炎（CAP）市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。また、当レポートでは、世界市場の主要プレイヤーを特定し、プロファイルを作成するとともに、市中肺炎（CAP）市場を綿密に分類・応用することで、読者が市場構造とダイナミクスをより正確に把握できるようにし、十分な情報に基づいた意思決定と戦略立案に強力なサポートを提供しています。

市中肺炎（CAP）のレポートは2019年から2030年までのタイプ別およびアプリケーション別、収益、成長率別のセグメントデータを分析します。収益、予測成長傾向、アプリケーション、およびエンドユーザー業界の市場規模を評価および予測します。

章の概要
第1章：市中肺炎（CAP）のレポートの報告範囲、各セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメント（製品タイプ、用途など）のエグゼクティブサマリーを紹介します。市場の現状と、短期から中期、および長期的な進化の可能性をハイレベルに見ることができます。（2019～2030）
第2章：市中肺炎（CAP）の世界及び地域レベルでの売上高。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界各国の市場発展、今後の発展展望、市場空間、生産能力などを紹介する。また、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界企業が直面する課題とリスク、業界の関連政策の分析などを紹介しています。（2019～2030）
第3章市中肺炎（CAP）企業の競争状況、収益、市場シェアと業界ランキング、最新の開発計画、合併・買収情報などの詳細分析。（2019～2030）
第4章：各市場セグメントの収益と開発の可能性をカバーし、種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2024）
第5章：市中肺炎（CAP）の各市場セグメントの収益と開発の可能性をカバーするアプリケーション別のさまざまな市場セグメントの分析を提供し、読者がさまざまな下流市場でブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：北米（米国、カナダ）のタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第7章：ヨーロッパのタイプ別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第8章：中国の種類別、および用途別、各セグメントの収益。（2019～2030）
第9章アジア（中国を除く）の種類別、用途別、地域別、セグメントごとの収益。（2019～2030）
第10章：中東、アフリカ、ラテンアメリカの種類別、アプリケーション別、国別、各セグメントの収益。（2019～2030）
第11章：市中肺炎（CAP）の主要企業の概要を提供し、製品の説明と仕様、市中肺炎（CAP）の収益、粗利益率、最近の展開など、市場の主要企業の基本状況を詳細に紹介します。（2019～2024）
第12章：アナリストの見解/結論

Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system.

Market Analysis and Insights: Global Community Acquired Pneumonia (CAP) Market
The global Community Acquired Pneumonia (CAP) market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and Latin America.

Report Covers:
This report presents an overview of global market for Community Acquired Pneumonia (CAP) market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030. 
This report researches the key producers of Community Acquired Pneumonia (CAP), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Community Acquired Pneumonia (CAP), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Community Acquired Pneumonia (CAP) revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Community Acquired Pneumonia (CAP) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Community Acquired Pneumonia (CAP) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer, Astrazeneca, Bioaegis Therapeutics, Biotest, C10 Pharma, Kyorin Pharmaceutical, Melinta Therapeutics, Merck and Nabriva Therapeutics, etc.

Market Segmentation
By Company
    Pfizer
    Astrazeneca
    Bioaegis Therapeutics
    Biotest
    C10 Pharma
    Kyorin Pharmaceutical
    Melinta Therapeutics
    Merck
    Nabriva Therapeutics
    Paratek Pharmaceuticals

Segment by Type
    Chest X-ray/Radiography
    Sputum Gram Stain and/or Culture
    Blood Cultures

Segment by Application
    Hospitals and Clinics
    Others

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        UK
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Community Acquired Pneumonia (CAP) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Community Acquired Pneumonia (CAP) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Community Acquired Pneumonia (CAP) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
    Table 1. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Chest X-ray/Radiography
    Table 3. Key Players of Sputum Gram Stain and/or Culture
    Table 4. Key Players of Blood Cultures
    Table 5. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 6. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 7. Global Community Acquired Pneumonia (CAP) Market Size by Region (2019-2024) & (US$ Million)
    Table 8. Global Community Acquired Pneumonia (CAP) Market Share by Region (2019-2024)
    Table 9. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 10. Global Community Acquired Pneumonia (CAP) Market Share by Region (2025-2030)
    Table 11. Community Acquired Pneumonia (CAP) Market Trends
    Table 12. Community Acquired Pneumonia (CAP) Market Drivers
    Table 13. Community Acquired Pneumonia (CAP) Market Challenges
    Table 14. Community Acquired Pneumonia (CAP) Market Restraints
    Table 15. Global Community Acquired Pneumonia (CAP) Revenue by Players (2019-2024) & (US$ Million)
    Table 16. Global Community Acquired Pneumonia (CAP) Revenue Share by Players (2019-2024)
    Table 17. Global Top Community Acquired Pneumonia (CAP) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2023)
    Table 18. Global Community Acquired Pneumonia (CAP) Industry Ranking 2022 VS 2023 VS 2024
    Table 19. Global 5 Largest Players Market Share by Community Acquired Pneumonia (CAP) Revenue (CR5 and HHI) & (2019-2024)
    Table 20. Global Key Players of Community Acquired Pneumonia (CAP), Headquarters and Area Served
    Table 21. Global Key Players of Community Acquired Pneumonia (CAP), Product and Application
    Table 22. Global Key Players of Community Acquired Pneumonia (CAP), Product and Application
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 25. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2019-2024)
    Table 26. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 27. Global Community Acquired Pneumonia (CAP) Revenue Market Share by Type (2025-2030)
    Table 28. Global Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 29. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2019-2024)
    Table 30. Global Community Acquired Pneumonia (CAP) Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 31. Global Community Acquired Pneumonia (CAP) Revenue Share by Application (2025-2030)
    Table 32. North America Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 33. North America Community Acquired Pneumonia (CAP) Market Size by Type (2025-2030) & (US$ Million)
    Table 34. North America Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 35. North America Community Acquired Pneumonia (CAP) Market Size by Application (2025-2030) & (US$ Million)
    Table 36. North America Community Acquired Pneumonia (CAP) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 37. North America Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024) & (US$ Million)
    Table 38. North America Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030) & (US$ Million)
    Table 39. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 40. Europe Community Acquired Pneumonia (CAP) Market Size by Type (2025-2030) & (US$ Million)
    Table 41. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 42. Europe Community Acquired Pneumonia (CAP) Market Size by Application (2025-2030) & (US$ Million)
    Table 43. Europe Community Acquired Pneumonia (CAP) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Europe Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030) & (US$ Million)
    Table 46. China Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 47. China Community Acquired Pneumonia (CAP) Market Size by Type (2025-2030) & (US$ Million)
    Table 48. China Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 49. China Community Acquired Pneumonia (CAP) Market Size by Application (2025-2030) & (US$ Million)
    Table 50. Asia Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 51. Asia Community Acquired Pneumonia (CAP) Market Size by Type (2025-2030) & (US$ Million)
    Table 52. Asia Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 53. Asia Community Acquired Pneumonia (CAP) Market Size by Application (2025-2030) & (US$ Million)
    Table 54. Asia Community Acquired Pneumonia (CAP) Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 55. Asia Community Acquired Pneumonia (CAP) Market Size by Region (2019-2024) & (US$ Million)
    Table 56. Asia Community Acquired Pneumonia (CAP) Market Size by Region (2025-2030) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2019-2024) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Type (2025-2030) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2019-2024) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Application (2025-2030) & (US$ Million)
    Table 61. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 62. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2019-2024) & (US$ Million)
    Table 63. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size by Country (2025-2030) & (US$ Million)
    Table 64. Pfizer Company Details
    Table 65. Pfizer Business Overview
    Table 66. Pfizer Community Acquired Pneumonia (CAP) Product
    Table 67. Pfizer Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 68. Pfizer Recent Developments
    Table 69. Astrazeneca Company Details
    Table 70. Astrazeneca Business Overview
    Table 71. Astrazeneca Community Acquired Pneumonia (CAP) Product
    Table 72. Astrazeneca Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 73. Astrazeneca Recent Developments
    Table 74. Bioaegis Therapeutics Company Details
    Table 75. Bioaegis Therapeutics Business Overview
    Table 76. Bioaegis Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 77. Bioaegis Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 78. Bioaegis Therapeutics Recent Developments
    Table 79. Biotest Company Details
    Table 80. Biotest Business Overview
    Table 81. Biotest Community Acquired Pneumonia (CAP) Product
    Table 82. Biotest Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 83. Biotest Recent Developments
    Table 84. C10 Pharma Company Details
    Table 85. C10 Pharma Business Overview
    Table 86. C10 Pharma Community Acquired Pneumonia (CAP) Product
    Table 87. C10 Pharma Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 88. C10 Pharma Recent Developments
    Table 89. Kyorin Pharmaceutical Company Details
    Table 90. Kyorin Pharmaceutical Business Overview
    Table 91. Kyorin Pharmaceutical Community Acquired Pneumonia (CAP) Product
    Table 92. Kyorin Pharmaceutical Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 93. Kyorin Pharmaceutical Recent Developments
    Table 94. Melinta Therapeutics Company Details
    Table 95. Melinta Therapeutics Business Overview
    Table 96. Melinta Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 97. Melinta Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 98. Melinta Therapeutics Recent Developments
    Table 99. Merck Company Details
    Table 100. Merck Business Overview
    Table 101. Merck Community Acquired Pneumonia (CAP) Product
    Table 102. Merck Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 103. Merck Recent Developments
    Table 104. Nabriva Therapeutics Company Details
    Table 105. Nabriva Therapeutics Business Overview
    Table 106. Nabriva Therapeutics Community Acquired Pneumonia (CAP) Product
    Table 107. Nabriva Therapeutics Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 108. Nabriva Therapeutics Recent Developments
    Table 109. Paratek Pharmaceuticals Company Details
    Table 110. Paratek Pharmaceuticals Business Overview
    Table 111. Paratek Pharmaceuticals Community Acquired Pneumonia (CAP) Product
    Table 112. Paratek Pharmaceuticals Revenue in Community Acquired Pneumonia (CAP) Business (2019-2024) & (US$ Million)
    Table 113. Paratek Pharmaceuticals Recent Developments
    Table 114. Research Programs/Design for This Report
    Table 115. Key Data Information from Secondary Sources
    Table 116. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Community Acquired Pneumonia (CAP) Market Share by Type: 2023 VS 2030
    Figure 3. Chest X-ray/Radiography Features
    Figure 4. Sputum Gram Stain and/or Culture Features
    Figure 5. Blood Cultures Features
    Figure 6. Global Community Acquired Pneumonia (CAP) Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 7. Global Community Acquired Pneumonia (CAP) Market Share by Application: 2023 VS 2030
    Figure 8. Hospitals and Clinics Case Studies
    Figure 9. Others Case Studies
    Figure 10. Community Acquired Pneumonia (CAP) Report Years Considered
    Figure 11. Global Community Acquired Pneumonia (CAP) Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Community Acquired Pneumonia (CAP) Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Community Acquired Pneumonia (CAP) Market Share by Region: 2023 VS 2030
    Figure 14. Global Community Acquired Pneumonia (CAP) Market Share by Players in 2023
    Figure 15. Global Top Community Acquired Pneumonia (CAP) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Community Acquired Pneumonia (CAP) as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Community Acquired Pneumonia (CAP) Revenue in 2023
    Figure 17. North America Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Community Acquired Pneumonia (CAP) Market Share by Type (2019-2030)
    Figure 19. North America Community Acquired Pneumonia (CAP) Market Share by Application (2019-2030)
    Figure 20. North America Community Acquired Pneumonia (CAP) Market Share by Country (2019-2030)
    Figure 21. United States Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Community Acquired Pneumonia (CAP) Market Size YoY (2019-2030) & (US$ Million)
    Figure 24. Europe Community Acquired Pneumonia (CAP) Market Share by Type (2019-2030)
    Figure 25. Europe Community Acquired Pneumonia (CAP) Market Share by Application (2019-2030)
    Figure 26. Europe Community Acquired Pneumonia (CAP) Market Share by Country (2019-2030)
    Figure 27. Germany Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. China Community Acquired Pneumonia (CAP) Market Size YoY (2019-2030) & (US$ Million)
    Figure 34. China Community Acquired Pneumonia (CAP) Market Share by Type (2019-2030)
    Figure 35. China Community Acquired Pneumonia (CAP) Market Share by Application (2019-2030)
    Figure 36. Asia Community Acquired Pneumonia (CAP) Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. Asia Community Acquired Pneumonia (CAP) Market Share by Type (2019-2030)
    Figure 38. Asia Community Acquired Pneumonia (CAP) Market Share by Application (2019-2030)
    Figure 39. Asia Community Acquired Pneumonia (CAP) Market Share by Region (2019-2030)
    Figure 40. Japan Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. South Korea Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Size YoY (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Share by Type (2019-2030)
    Figure 48. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Share by Application (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Community Acquired Pneumonia (CAP) Market Share by Country (2019-2030)
    Figure 50. Brazil Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Mexico Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Turkey Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Israel Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. GCC Countries Community Acquired Pneumonia (CAP) Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Pfizer Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 57. Astrazeneca Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 58. Bioaegis Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 59. Biotest Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 60. C10 Pharma Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 61. Kyorin Pharmaceutical Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 62. Melinta Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 63. Merck Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 64. Nabriva Therapeutics Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 65. Paratek Pharmaceuticals Revenue Growth Rate in Community Acquired Pneumonia (CAP) Business (2019-2024)
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed